CJC-1295
PeptideA synthetic peptide that stimulates growth hormone release by binding to GHRH receptors. Used for muscle growth, fat loss, and recovery. Often combined with ipamorelin.
Evidence comparisons not yet run for these claims.
Expert Consensus
Evidence Summary
Significant limitations exist across the board. There are no clinical trials in this dataset evaluating CJC-1295's effects on body composition, growth hormone levels, recovery, or any other outcome. The sole study provides no quantitative data, no control group, and no verified health outcomes — only anecdotal, self-reported accounts from an unspecified online population. The long-term safety profile of CJC-1295, potential hormonal side effects, optimal dosing, and interactions with other substances remain entirely uncharacterized by the research reviewed here. Anyone considering this supplement should be aware that the evidence base, at least as represented here, does not support evidence-based decision-making.
Read full evidence summary →Top studies
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Expert Mentions
All 9 mentions
“it's worse if you drink alcohol if you have wine so I had wine and then I injected and I felt like I was on fire”
The burning sensation from CJC-1295 is worse if you have consumed alcohol beforehand.
“it's worse if you drink alcohol if you have wine so I had wine and then I injected and I felt like I was on fire”
The burning sensation from CJC-1295 is worse if you have consumed alcohol beforehand.
Safety, interactions & who should avoid CJC-1295
The reviewed research provides no data on the safety profile of CJC-1295. Given the complete absence of clinical trial data in this dataset, potential risks, side effects, and contraindications cannot be assessed.
CJC-1295 is a synthetic peptide not approved by the FDA for general use and is banned by WADA. Reported side effects include a transient whole-body flushing or burning sensation post-injection. Risks include water retention, potential impact on insulin sensitivity, and unknown long-term consequences. Purity and sterility of non-pharmaceutical-grade peptides pose additional serious risks.
Who should avoid it
Individuals with active malignancy, diabetes or insulin resistance, pituitary disorders, pregnancy or breastfeeding, or those under 18 should avoid use. Anyone with a history of cancer should exercise particular caution given GH's potential proliferative effects.
Known interactions
- ·May interact with insulin or antidiabetic medications by affecting glucose metabolism
- ·Potential additive effects with other GH secretagogues or exogenous growth hormone, increasing risk of side effects
- ·May interact with corticosteroids, which can blunt GH axis activity
Pregnancy & breastfeeding
Our sources specifically flag pregnancy or breastfeeding considerations for CJC-1295 — see the cautions above.
We don’t assign pregnancy-safety ratings. Many supplements lack adequate safety data in pregnancy and breastfeeding, and the absence of a warning here does not mean a supplement is safe to take. Don’t start, stop, or continue any supplement while pregnant or nursing without your OB-GYN or midwife.
Read: Supplements during pregnancy & breastfeeding →This is educational information only. Consult a healthcare provider before starting any supplement.
Stay on top of CJC-1295 research
One email a month when new research on CJC-1295 is published.
Double opt-in · unsubscribe anytime · not medical advice.
No buy link — yet
We only link products that meet our sourcing standards. We haven’t linked one for CJC-1295 yet. Our standards →
Key findings
- ·Only one study was identified, and it was a netnography (qualitative analysis of online discussions), not a clinical trial.
- ·The study focused exclusively on female use patterns and self-reported experiences with CJC-1295 in online communities.
- ·No quantitative outcomes, population sizes, or specific findings were available from the study.
Evidence gaps
- ·There are no clinical trials in the reviewed literature measuring the actual physiological effects of CJC-1295 in humans, including impacts on growth hormone levels, body composition, or recovery.
- ·The safety profile of CJC-1295 — including hormonal side effects, long-term risks, and drug interactions — is completely unaddressed by the available research.
- ·Effective dosing, timing, and population-specific responses (e.g., by sex, age, or health status) have not been studied in the provided evidence base.